Skip to main content
Premium Trial:

Request an Annual Quote

University of Bordeaux Starts New Biomarker Research Facility

NEW YORK (GenomeWeb News) — The Biomedical Innovation Platform (PTIB) at France's University Hospital of Bordeaux has launched a new biomarker research facility and plans in the coming year to open a next-generation sequencing center.
The new molecular core facility is the product of a partnership between the University Hospital of Bordeaux and the Regional Council of Aquitaine.
The facility is stocked with tools and technologies from Roche, Eurogentec, Beckman Coulter, Agencourt, DNAgenotek, and Biomek.
"Our first project will address mitochondrial DNA diversity and relationship with aging related diseases on a population of 3,000 patients and a selection of more than 250 mtSNP markers,” Patrick Merel, director of the molecular core facility, explained.
PTIB currently has four core facilities including a bioimaging laboratory; a molecular core lab; a histology, immunology, and cellular core lab; and an electrophysiology facility. It also hosts a biomaterial, medical device, and tissue-engineering working group, the Platelet Pathology National Reference Center, which is part of the French National Plan for Rare Diseases.
PTIB also serves as a biotechnology incubator that allows companies to share infrastructure and equipment.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.